Delayed traumatic rupture of colon with colocutaneous fistula.

(whether methysergide or Demigran) was preferred by 16 patients, and that given second was preferred by 12, a nonsignificant difference. ADDENDUM.-Since the completion of this trial we have been advised by the manufacturers of Demigran that its formulation has been altered to give more satisfactory absorption characteristics when administered by mouth. We have been assured that this modification has been achieved without affecting its pharmacological properties in any way. Further, we have been told that in Europe, where the drug is in more general clinical use, higher doses than those originally recommended are now being given. We have therefore decided to embark on a further trial of this drug with the modified preparation and the new dosage schedules. The results of that study will be reported in due course.